Amgen Inc. stock climbed Wednesday after Roche Holding AG of Switzerland delayed a plan to submit its anemia drug for U.S. regulatory approval, further opening the opportunity for Amgen’s drug, Aranesp.
Amgen Inc. stock climbed Wednesday after Roche Holding AG of Switzerland delayed a plan to submit its anemia drug for U.S. regulatory approval, further opening the opportunity for Amgen’s drug, Aranesp.
